• Corpus ID: 32027651

Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription.

  title={Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription.},
  author={Jacqueline A. Sparks and Barry L Duncan},
  journal={Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent},
  volume={22 3},
  • J. SparksB. Duncan
  • Published 1 August 2013
  • Psychology, Medicine
  • Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
OBJECTIVE The purpose of this review is to assess whether evidence supports a favorable risk/benefit profile for pediatric antidepressant use and reconsideration of the black box. METHOD The review examines studies post-black box purporting to show declines in pediatric antidepressant use and rising youth suicide, summarizes evidence for efficacy and safety of pediatric antidepressants, and discusses irregularities in recent meta-analyses of fluoxetine for youth. RESULTS Pediatric… 

Figures from this paper

Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified

The Black Box warning is firmly rooted in solid data whereas attempts to claim the warning has caused harm are based on quite weak evidence.

Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning.

Long-run trends in antidepressant use among children before and after the black box warning for those with and without severe psychological impairment are analyzed, raising concern that the impact of the warning may have dissipated over time.

Starting Young: Children Cultured into Becoming Psycho-Pharmaceutical Consumers—The Example of Childhood Depression

This chapter critically analyses three of the academic papers that received extensive media coverage and encouraged a resumption of the prescribing of antidepressants to the young and outlines how the concept of ‘childhood depression’ changed from something perceived to be rare, different to adult depression, and not responsive to antidepressant medication to something common, similar to adult Depression.

Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia.

It was found that a significant portion of adolescents had treatment-emergent suicidal ideation and behaviour as well as other severe psychiatric adverse events with duloxetine, but no such events were recorded on placebo.

The treatment of major depression with fluoxetine

Fluoxetine is one of the few antidepressants licensed for use in children under the age of 18 years in the UK and this simplifies therapy and may improve outcomes but it induces a number of side effects like, nausea, insomnia, sexual dysfunction and its interaction with monoamine oxidase inhibitors can cause the serotonin syndrome.

Present and future of developmental neuropsychopharmacology

  • C. Arango
  • Psychology, Medicine
    European Neuropsychopharmacology
  • 2015

Depression: Current treatments with low-cost strategies

Electroconvulsive therapy has been used in the treatment of depression since the late 1930s and is effective particularly in severe depression, and it is quick acting, but its use tend to evoke moral and ethical debates.

Management of anxiety disorders in children with attention-deficit hyperactivity disorder: a narrative review

Adjunctive cognitive-behavior therapy for anxiety disorder symptoms is strongly recommended and is considered superior to medication alone, and in moderate and severe cases of comorbid Ads, selective serotonin reuptake inhibitors can be added to the stimulants, with the required caution.

Psychiatric Drugging of Children and Youth as a Form of Child Abuse: Not a Radical Proposition

Although affirming that the psychiatric drugging of children constitutes both adultism (oppression based on treating adult behavior as normative) and sanism (oppression based on prioritizing what are

On Becoming a Better Therapist: Evidence-Based Practice One Client at a Time

How can therapists become better at doing what they love, avoid burnout, and prevent client dropout? Respected therapist, trainer, and researcher Barry Duncan asserts that getting better at this work



An update on antidepressant use and suicidality in pediatric depression

This review provides an overview of the temporal associations of regulatory agencies' actions in North America and Europe with rates of depression diagnoses, pediatric antidepressant prescription rates, follow-up visits to physicians prescribing antidepressants, and rates of completed suicide and suicidal ideation in children and adolescents.

How do we Safely Treat Depression in Children, Adolescents and Young Adults?

The evidence is unfavourable for antidepressants in this population on important measures such as mortality, hospitalization and quality of life, and an approach is suggested that primary care physicians might adopt with their depressed young patients.

Efficacy and safety of antidepressants for children and adolescents

Of seven published randomised controlled trials of newer antidepressants for depressed children published in refereed journals, six used a placebo control and the extent to which authors' conclusions were supported by data was analysed.

Efficacy of antidepressants in juvenile depression: meta-analysis

Antidepressants of all types showed limited efficacy in juvenile depression, but fluoxetine might be more effective, especially in adolescents.

Suicidality in pediatric patients treated with antidepressant drugs.

Use of antidepressant drugs in pediatric patients is associated with a modestly increased risk of suicidality, and a meta-analysis was conducted to obtain overall suicidity risk estimates.

Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

This is the first research synthesis of suicidal thoughts and behavior in depressed patients treated with antidepressants that examined the mediating role of depressive symptoms using complete longitudinal person-level data from a large set of published and unpublished studies.

Effects of Food and Drug Administration warnings on antidepressant use in a national sample.

The paroxetine and black box warnings had modest and relatively targeted effects on the intended populations, and changes in antidepressant use were less pronounced in adults than in youth.

National trends in prescribing antidepressants before and after an FDA advisory on suicidality risk in youths.

Children's depression visits and visits with an antidepressant prescribed dropped after the advisory, but children with major depressive disorder appeared no less likely to be prescribed antidepressants.

Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and Ongoing Management

These guidelines cannot replace clinical judgment, and they should not be the sole source of guidance for adolescent depression management, but they may assist primary care clinicians in the management of depressed adolescents in an era of great clinical need and a shortage of mental health specialists.